Maggie Lo-Yee Yau1, Eva Lai-Wah Fung1, Pak Cheung Ng1. 1. Maggie Lo-Yee Yau, Eva Lai-Wah Fung, Pak Cheung Ng, Department of Paediatrics, the Chinese University of Hong Kong, Hong Kong, China.
Abstract
AIM: To review the clinical response to levetiracetam (LEV) in neonatal seizure management in intensive care unit. METHODS: Medical records of neonates who received LEV from January 2009 to August 2014 were reviewed. Their demographic data, clinical characteristics, etiology, seizures, electroencephalograms, response to treatment and outcome were noted. Literature review of use of LEV in neonates were also performed via PubMed and EMBASE with keywords - "neonates", "seizures", "epilepsy" and "LEV" up to Sep 2014 and retrieved the publications. The response rate to LEV was compared. RESULTS: Twelve neonates were identified during the study period. All patients received phenobarbitone loading prior to consideration of LEV. Seven (58%) and nine (75%) achieved seizure freedom 24 h and 72 h after LEV was added, both clinically and electrographically. No serious adverse effects were associated with LEV use. From the literature, there are total 144 neonates reported to have used LEV. The overall results suggested that LEV could control up to 90% of neonatal seizures. CONCLUSION: LEV was found to be relatively safe and efficacious in treating neonatal seizures, but might not work well in the most severe hypoxic ischemic encephalopathy.
AIM: To review the clinical response to levetiracetam (LEV) in neonatal seizure management in intensive care unit. METHODS: Medical records of neonates who received LEV from January 2009 to August 2014 were reviewed. Their demographic data, clinical characteristics, etiology, seizures, electroencephalograms, response to treatment and outcome were noted. Literature review of use of LEV in neonates were also performed via PubMed and EMBASE with keywords - "neonates", "seizures", "epilepsy" and "LEV" up to Sep 2014 and retrieved the publications. The response rate to LEV was compared. RESULTS: Twelve neonates were identified during the study period. All patients received phenobarbitone loading prior to consideration of LEV. Seven (58%) and nine (75%) achieved seizure freedom 24 h and 72 h after LEV was added, both clinically and electrographically. No serious adverse effects were associated with LEV use. From the literature, there are total 144 neonates reported to have used LEV. The overall results suggested that LEV could control up to 90% of neonatal seizures. CONCLUSION:LEV was found to be relatively safe and efficacious in treating neonatal seizures, but might not work well in the most severe hypoxic ischemicencephalopathy.
Authors: Petra Bittigau; Marco Sifringer; Kerstin Genz; Ellen Reith; Dana Pospischil; Suresh Govindarajalu; Mark Dzietko; Stefanie Pesditschek; Ingrid Mai; Krikor Dikranian; John W Olney; Chrysanthy Ikonomidou Journal: Proc Natl Acad Sci U S A Date: 2002-11-04 Impact factor: 11.205
Authors: M J Painter; M S Scher; A D Stein; S Armatti; Z Wang; J C Gardiner; N Paneth; B Minnigh; J Alvin Journal: N Engl J Med Date: 1999-08-12 Impact factor: 91.245
Authors: Stephanie L Merhar; Kurt R Schibler; Catherine M Sherwin; Jareen Meinzen-Derr; Jing Shi; Tonya Balmakund; Alexander A Vinks Journal: J Pediatr Date: 2011-05-18 Impact factor: 4.406
Authors: Cynthia M Sharpe; Edmund V Capparelli; Andrew Mower; Michael J Farrell; Steven J Soldin; Richard H Haas Journal: Pediatr Res Date: 2012-04-11 Impact factor: 3.756
Authors: Ronit M Pressler; Geraldine B Boylan; Neil Marlow; Mats Blennow; Catherine Chiron; J Helen Cross; Linda S de Vries; Boubou Hallberg; Lena Hellström-Westas; Vincent Jullien; Vicki Livingstone; Barry Mangum; Brendan Murphy; Deirdre Murray; Gerard Pons; Janet Rennie; Renate Swarte; Mona C Toet; Sampsa Vanhatalo; Sarah Zohar Journal: Lancet Neurol Date: 2015-03-10 Impact factor: 44.182